The genesis and evolution of high-grade serous ovarian cancer

Germline mutation in either BRCA1 or BRCA2 is associated with an increased risk of ovarian cancer, particularly the most common invasive histotype — serous carcinoma. In addition, serous ovarian cancers have an unusually high frequency of other molecular events involving BRCA pathway dysfunction. Recent findings show a high frequency of TP53 mutation, chromosomal instability, distinct molecular subtypes and DNA copy number-driven changes in gene expression. These findings suggest a model in which homologous recombination repair deficiency initiates a cascade of molecular events that sculpt the evolution of high-grade serous ovarian cancer and dictate its response to therapy.

[1]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[2]  J. Marto,et al.  Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.

[3]  James M. Roberts,et al.  A mouse model for cyclin E-dependent genetic instability and tumorigenesis. , 2005, Cancer cell.

[4]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[5]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[6]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[7]  B. Stewart,et al.  World Cancer Report , 2003 .

[8]  Shelley Tworoger,et al.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. , 2008, Gynecologic oncology.

[9]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[10]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[11]  Yuan Zhang,et al.  Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting fanconi anemia-BRCA pathway , 2006, Cancer biology & therapy.

[12]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[13]  A. Oza,et al.  Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. , 2010 .

[14]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[15]  R. Buller,et al.  Frequency of BRCA1 dysfunction in ovarian cancer. , 2002, Journal of the National Cancer Institute.

[16]  Francis S. Collins,et al.  Mapping the cancer genome , 2007 .

[17]  Francis S Collins,et al.  Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. , 2007, Scientific American.

[18]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[19]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[20]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[21]  T. Crook,et al.  Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer , 2008, British Journal of Cancer.

[22]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[23]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[24]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[25]  E. Williamson,et al.  BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1 , 2006, Oncogene.

[26]  Peter Simpson,et al.  DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. , 2010, American journal of human genetics.

[27]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[28]  Luke Hughes-Davies,et al.  EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.

[29]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[30]  E. Williamson,et al.  BRCA1 transactivates the cyclin-dependent kinase inhibitor p27Kip1 , 2002, Oncogene.

[31]  B. Ponder,et al.  Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. , 1999, Molecular cell.

[32]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010 .

[33]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[34]  Ashok R Venkitaraman,et al.  Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. , 2009, Annual review of pathology.

[35]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[36]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[37]  A. D’Andrea.  The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers , 2003, Cell cycle.

[38]  S. Kobayashi.  Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance , 2008, Breast cancer.

[39]  Kylie L. Gorringe,et al.  Large‐scale genomic analysis of ovarian carcinomas , 2009, Molecular oncology.

[40]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[42]  R. Berkowitz,et al.  The Li–Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube , 2010, The Journal of pathology.

[43]  Kathleen R. Cho,et al.  Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. , 2003, Cancer research.

[44]  A. Børresen-Dale,et al.  COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.

[45]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[46]  Lawrence S. Hon,et al.  High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors , 2009, BMC Medical Genomics.

[47]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[48]  M. Muto,et al.  Advances in the Recognition of Tubal Intraepithelial Carcinoma: Applications to Cancer Screening and the Pathogenesis of Ovarian Cancer , 2006, Advances in anatomic pathology.

[49]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[50]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[51]  B. Rosen,et al.  Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma , 2008, Clinical Cancer Research.

[52]  R. Young,et al.  The Distinction Between Primary and Metastatic Mucinous Carcinomas of the Ovary: Gross and Histologic Findings in 50 Cases , 2003, The American journal of surgical pathology.

[53]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[55]  Gordon B Mills,et al.  Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon , 2005, Clinical Cancer Research.

[56]  J. Jass.  Colorectal cancer: a multipathway disease. , 2006, Critical reviews in oncogenesis.

[57]  Ross S Berkowitz,et al.  Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Vincent-Salomon,et al.  High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.

[59]  R. Drapkin,et al.  Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer , 2007, Clinical Medicine & Research.

[60]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[61]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[62]  R. Buller,et al.  Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.

[63]  Rochelle L. Garcia,et al.  The molecular pathogenesis of hereditary ovarian carcinoma , 2010, Cancer.